AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04823832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: resection of the head of pancreas and the duodenum followed by triple anastomosis
Study NCT03905980 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal delivery
Description: pregnancy ended by vaginal delivery
Study NCT03905980 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean section
Description: pregnancy ended by cesarean delivery
Study NCT00573313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine
Description: Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
Study NCT00573313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
Study NCT03191175 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: 47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
Study NCT04716582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting interrupted by light physical activity
Description: Each 30 minutes will be 25 minutes sitting followed by 5 minutes walking that designed as prescribed walking route outside laboratory corridor.
Study NCT04716582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting with cognitive task
Description: Participants will perform online cognitive task during prolonged sitting.
Study NCT04716582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: uninterrupted sitting
Description: Participants will watch documentary during prolonged sitting.
Study NCT00548314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermal matrix
Description: 1mm thickness matrix composed of collagen-elastin hydrolosate
Study NCT00548314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split skin graft
Study NCT00548314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC therapy (KCI)
Description: VAC therapy for 3-5 days 125mmHg
Study NCT02681939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulsi(Ocimum sanctum Linn.) capsules
Study NCT05091151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg
Description: Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
Study NCT03317444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC101
Description: Oral suspension
Study NCT03317444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT03251755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Exercise promotion using Chinese Yoga
Study NCT04474405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 MBq (10 mCi), single dose
Study NCT04474405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
Study NCT04474405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain PET Scan
Description: positron emission tomography (PET) scan of the brain starting immediately after administration (60 minute dynamic imaging plus 4 frames x 5 minutes at approximately 80 minutes post-dose).
Study NCT04474405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body PET scan
Description: positron emission tomography (PET) scan of the body from the vertex of the head to the thighs starting immediately following injection and repeated over 6 hours
Study NCT04474405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: IV injection, 370 MBq (10 mCi), single dose
Study NCT04474405 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Florbetapir F 18
Description: IV injection, 370 MBq (10 mCi), single dose
Study NCT04474405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
Study NCT04474405 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain MRI
Description: Volume-based T1-weighted Magnetic Resonance Imaging (MRI) of the brain
Study NCT01473173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420
Study NCT01473173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Study NCT02369822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
Study NCT03442530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ToPIC
Description: Expanded tobacco cessation counseling for pregnant women.
Study NCT03442530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Treatment As Usual (TTAU)
Description: Standard of care tobacco cessation counseling for pregnant women
Study NCT03261167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (GSK1358820)
Description: GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
Study NCT03261167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (GSK1358820)
Description: GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
Study NCT03261167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo injection will contain sodium chloride (0.9 mg).
Study NCT01439451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
Study NCT01439451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
Study NCT04439669 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham nrTMS and open phase
Description: Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2.
Study NCT04439669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active nrTMS and open phase
Description: Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2.
Study NCT03530540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity extracorporeal shockwave therapy
Description: Active shockwaves
Study NCT03530540 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LI-ESWT
Description: Placebo shockwaves
Study NCT03530540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile pump
Description: both groups will be treated with a penile pump
Study NCT03530540 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Penile pump
Description: both groups will be treated with a penile pump
Study NCT00465738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)
Description: active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
Study NCT00465738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)
Description: active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
Study NCT00820040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular porcine dermal collagen mesh
Description: porcine mesh for hernia repair/ abdominal wall reconstruction
Study NCT02058381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib (BYL719)
Description: BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
Study NCT04935554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Person centred care
Description: physical activity, nutrition, motivation, health competence, psychosocial.
Study NCT00835614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil for oral suspension 250 mg/5 mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study NCT00835614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFZIL® for Oral Suspension 250 mg/5mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study NCT02058381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib (BKM120)
Description: BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
Study NCT03411070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo SCOUT reflector placement
Study NCT03411070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04557345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional transthoracic echocardiogram
Description: With prior informed consent, a two-dimensional transthoracic echocardiogram will be obtained by an echocardiographer certified by the Mexican Council of Cardiology (CMC) with a Phillips EPIC 7 echocardiography, 2D Arrary 3D Convex (1-6 Mhz) transducer.
Study NCT01370954 — intervention group
Intervention type: OTHER
Intervention: CerefolinNAC®
Description: CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
Study NCT02856737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye masks and earplugs
Description: Materials similar to those offered on long commercial flights
Study NCT03269006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inesfly Paint
Description: Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin
Study NCT03269006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDWL (1m)
Description: Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
Study NCT03269006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITN (KO-Tab 123)
Description: Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
Study NCT03269006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRS (Delthamethrin)
Description: Indoor residual spraying with Delthamethrin in the living rooms
Study NCT02400736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: Individual Placement and Support (IPS) is the evidenced based model of supported employment.
Study NCT02400736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual Vocational Rehabilitation/Transitional Work (TUA-VR)
Description: Vocational Rehabilitation Treatment as Usual includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW).
Study NCT01078428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical silicone gel
Description: Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
Study NCT01078428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
Study NCT02955927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Study NCT02955927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ortho-k
Study NCT02955927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ortho-k
Study NCT02765893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Foley
Description: Patients will have Foley catheter removed 6 hours post-op.
Study NCT02542345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study NCT04764604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Choice
Description: 3 minutes of exercise consisting of blowing through the device (on setting '5') and phonating at the same time.
Study NCT05634564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
Study NCT05634564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
Study NCT05634564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
Study NCT05634564 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with simultaneous integrated boost
Description: Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
Study NCT03548428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV every 3 weeks for 4 months
Study NCT04764604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube-in-water
Description: 3 minutes of exercise consisting of blowing through a silicone tube (10mm internal diameter) submerged in 5 cm of water whilst phonating at the same time.
Study NCT01996540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional arm: Early best palliative care
Description: Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
Study NCT01305343 — intervention group
Intervention type: PROCEDURE
Intervention: Routinely performed surgical correction of spinal deformity
Description: Routinely performed surgical correction of spinal deformity
Study NCT03589053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic conditioning
Description: The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
Study NCT03589053 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Participants in the control group receive both sham LRIC and standard clinical therapy.
Study NCT00999570 — intervention group
Intervention type: OTHER
Intervention: Specialty training for knee surgeons
Study NCT03367585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Physical exercise + Vitamin D3
Description: Strength exercise + Supplementation of vitamin D3 50,000 IU / week
Study NCT03367585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical exercise
Description: Strength exercise
Study NCT04119336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given intravenously once per cycle
Study NCT04119336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given orally on days 1, 8, 15.
Study NCT04119336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally on days 1, 8, 15, 22
Study NCT04119336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously on days 1, 8, 15.
Study NCT03548428 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 3 to 5 fractions depending on tumor size
Study NCT01263379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Description: This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein.
Study NCT03688737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
Study NCT03688737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo like device as it like low level laser device shape but with no effect to blind the intervention
Study NCT02347007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almond
Description: Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
Study NCT02347007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Bar
Description: Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
Study NCT02126202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography and revascularization if feasible
Description: Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
Study NCT03521336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
Study NCT03521336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline，Sham operation
Study NCT03483090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse High Strength Deep Sea Krill Oil
Description: Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
Study NCT03483090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No therapeutic effect
Study NCT03548428 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: 3 to 5 fractions depending on tumor size
Study NCT03008512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM